Efficacy and Safety of Immune Checkpoint Inhibitor Rechallenge in the Treatment of Esophageal Squamous Cell Cancer

Overview

Journal J Cancer

Date 2025 Jan 9

PMID 39781362

Authors

Xiaojing Zhang

Jingze Zhang

Junyi He

Xiao Zhong

Jinming Yu

Linlin Wang

Affiliations

Soon will be listed here.

Abstract

Rechallenge with immune checkpoint inhibitors (ICI) shows promise in various cancers, but data in esophageal squamous cell carcinoma (ESCC) is limited. This study aimed to evaluate the efficiency and safety of ICI rechallenge in ESCC. This multicenter study analyzed ESCC patients rechallenged with ICI from January 2020 to March 2023 across two medical institutions. Patients were divided into rechallenge (R) and non-rechallenge (NR) groups. Key outcomes studied were progression-free survival (PFS), overall survival (OS), and safety. Among 329 included ESCC patients, 211 were in the R group and 118 in the NR group, with a median follow-up of 17.1 months. The R group exhibited significantly prolonged median PFS (4.7 vs. 3.2 months; p <.001) and OS (9.3 vs. 6.2 months; p <.001) compared to the NR group. Notably, for patients who initially received radiotherapy, the R group showed significantly longer mPFS (5.1 vs. 3.2 months; p <.001) and mOS (10.4 vs. 5.9 months; p <.001). Incidences of all-grade (64.5% vs. 66.1%; p = .764) and grade ≥3 adverse events (17.5% vs. 18.6%; p = .802) did not significantly differ between groups. ICI rechallenge demonstrates efficacy and manageable safety in ESCC, particularly post-radiotherapy.

References

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D . Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3):351-357. PMC: 5885829. DOI: 10.1001/jamaoncol.2017.4771. View

Lin M, Li Y, Wu S, Sun J, Lin H, Zhang S . Differences in esophageal cancer characteristics and survival between Chinese and Caucasian patients in the SEER database. Onco Targets Ther. 2016; 9:6435-6444. PMC: 5077267. DOI: 10.2147/OTT.S112038. View

He K, Barsoumian H, Sezen D, Puebla-Osorio N, Hsu E, Verma V . Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Front Oncol. 2021; 11:737425. PMC: 8419338. DOI: 10.3389/fonc.2021.737425. View

Abou Alaiwi S, Xie W, Nassar A, Dudani S, Martini D, Bakouny Z . Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer. 2020; 8(1). PMC: 7057439. DOI: 10.1136/jitc-2019-000144. View

Kuczynski E, Sargent D, Grothey A, Kerbel R . Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol. 2013; 10(10):571-87. PMC: 4540602. DOI: 10.1038/nrclinonc.2013.158. View

Bimbatti D, Maruzzo M, Pierantoni F, Diminutto A, Dionese M, Deppieri F . Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature. Crit Rev Oncol Hematol. 2022; 170:103579. DOI: 10.1016/j.critrevonc.2022.103579. View

Cao W, Chen H, Yu Y, Li N, Chen W . Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021; 134(7):783-791. PMC: 8104205. DOI: 10.1097/CM9.0000000000001474. View

Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron T . Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008; 181(5):3099-107. PMC: 2587101. DOI: 10.4049/jimmunol.181.5.3099. View

Gobbini E, Toffart A, Perol M, Assie J, Duruisseaux M, Coupez D . Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer. 2020; 21(5):e497-e510. DOI: 10.1016/j.cllc.2020.04.013. View

10.

Swetter S, Thompson J, Albertini M, Barker C, Baumgartner J, Boland G . NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(4):364-376. DOI: 10.6004/jnccn.2021.0018. View

11.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

12.

Inomata M, Hirai T, Seto Z, Tokui K, Taka C, Okazawa S . Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy. Pathol Oncol Res. 2018; 26(1):327-333. DOI: 10.1007/s12253-018-0473-x. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Sullivan R, Atkins M, Kirkwood J, Agarwala S, Clark J, Ernstoff M . An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018; 6(1):44. PMC: 5977556. DOI: 10.1186/s40425-018-0362-6. View

15.

Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T . Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep. 2022; 5(1):100620. PMC: 9791167. DOI: 10.1016/j.jhepr.2022.100620. View

16.

Cai Z, Zhan P, Song Y, Liu H, Lv T . Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2022; 11(8):1555-1566. PMC: 9459604. DOI: 10.21037/tlcr-22-140. View

17.

Li L, Liu T, Liu Q, Mu S, Tao H, Yang X . Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer. Front Pharmacol. 2022; 13:967559. PMC: 9485935. DOI: 10.3389/fphar.2022.967559. View

18.

Gul A, Stewart T, Mantia C, Shah N, Stern Gatof E, Long Y . Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. J Clin Oncol. 2020; 38(27):3088-3094. PMC: 7499610. DOI: 10.1200/JCO.19.03315. View

19.

Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A . STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014; 41(5):843-52. PMC: 5155593. DOI: 10.1016/j.immuni.2014.10.019. View

20.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W . Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017; 111:176-181. DOI: 10.1016/j.lungcan.2017.07.024. View